| Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? | |
| | |
MedLine Citation:
|
PMID: 17694309 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: In patients with lymphoma, we investigated the impact of contrast-enhanced CT on PET attenuation correction in lesions and normal tissues, particularly when PET/CT was performed after chemotherapy. METHODS: Fifty patients (51+/-18 years) with Hodgkin's disease (n=17) or non-Hodgkin lymphomas (n=33) were studied before and after chemotherapy. PET/CT scans were performed 60 min after injection of FDG. Iopamiron 300 (iopamidol, 1.5 cc/kg) was injected immediately afterwards, followed 50 s later by a second craniocaudal CT (CT+). PET images were successively reconstructed using the unenhanced CT (PET-) and the CT+ (PET+) for attenuation correction, using iterative reconstruction (4 iterations, 8 subsets, 5 mm post-filtering). HU(mean), SUV(max) and SUV(mean) were measured before and after chemotherapy in ten non-tumoural ROIs [aorta, femur, kidney, lung, iliopsoas muscle, occipital cortex, T12 vertebra, liver, spleen and inferior vena cava (IVC)] and in tumoural lymphadenopathies or malignant tissues (n=397 and 51 VOIs respectively before and after chemotherapy) using a 3D-thresholding method (identical threshold for PET- and PET+). ROIs were defined on the PET- and automatically applied on the unenhanced CT (CT-), the CT+ and the PET+. RESULTS: In the non-tumoural tissues, HU(mean) increased significantly in the CT+ compared with the CT- in the vessels and the highly vascularised organs, and slight increases were observed in the occipital cortex (+11%), the iliopsoas muscle (+6%) and the femur (+3%). SUV(max) increased significantly in the PET+ compared with the PET- in the aorta (+14%), the liver (+10%), the spleen (+10%) and the IVC (+12%). SUV(mean) increased significantly in the PET+ compared with the PET- in the aorta (+15%), the kidney (+13%), the liver (+11%), the spleen (10%) and the IVC (+12%). In the lesions, HU(mean) was not significantly different before and after chemotherapy, whatever the normal region considered. SUV(max) increased significantly after treatment in the T12 vertebra (+12%). SUV(mean) increased significantly after treatment in the T12 vertebra (+13%) and in the liver (+12%). HU(mean) increased significantly in the CT+ compared with the CT- in the lesions (+55%) before chemotherapy. SUV(max) and SUV(mean) increased significantly in the PET+ compared with the PET- in the lesions (+4%) only before chemotherapy. No significant difference was seen in measurements (HU(mean), SUV(max) and SUV(mean)) after chemotherapy. CONCLUSION: Our study demonstrates that use of enhanced CT for attenuation correction has a negligible effect on quantification at staging and after chemotherapy. A "single-shot" enhanced PET/CT may thus be performed in the evaluation of patients with lymphoma at staging, during treatment and at follow-up. |
| | |
Authors:
|
Pierre Vera; Matthieu John Ouvrier; Sébastien Hapdey; Marc Thillays; Anne Sophie Pesquet; Brigitte Diologent; Françoise Callonec; Anne Hitzel; Agathe Edet-Sanson; Jean François Ménard; Fabrice Jardin; Hervé Tilly |
Related Documents
:
|
10329749 - Statistical parametric mapping with 18f-dopa pet shows bilaterally reduced striatal and... 22215879 - Mri of the cervical spine with neck extension: is it useful? 17989329 - Multimodality imaging of direct ureteric involvement in non-hodgkin's lymphoma using pe... 10203099 - Role of positron emission tomography in determining the extent of cns ischemia in patie... 20708809 - Detection and compensation of organ/lesion motion using 4d-pet/ct respiratory gated acq... 17015899 - Whole-body pet/ct with 11c-meta-hydroxyephedrine in tumors of the sympathetic nervous s... 17117089 - Focal f-18 fdg uptake mimicking malignant gastric localizations disappearing after wate... 2165209 - In vivo nuclear overhauser effect in 31p-(1h) double-resonance experiments in a 1.5-t w... 17963089 - Long-term follow-up of a patient with traumatic brain injury using diffusion tensor ima... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-08-11 |
Journal Detail:
|
Title: European journal of nuclear medicine and molecular imaging Volume: 34 ISSN: 1619-7070 ISO Abbreviation: Eur. J. Nucl. Med. Mol. Imaging Publication Date: 2007 Dec |
Date Detail:
|
Created Date: 2008-02-18 Completed Date: 2008-06-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101140988 Medline TA: Eur J Nucl Med Mol Imaging Country: Germany |
Other Details:
|
Languages: eng Pagination: 1943-52 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, Henri Becquerel Centre and Rouen University Hospital, 1 rue d'Amiens, Rouen, France. pierre.vera@rouen.fnclcc.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage* Artifacts Contrast Media* Female Humans Lymphoma / drug therapy*, radiography* Male Middle Aged Positron-Emission Tomography / methods* Reproducibility of Results Sensitivity and Specificity Subtraction Technique* Tomography, X-Ray Computed / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Contrast Media |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Renal accumulation of [111In]DOTATOC in rats: influence of inhibitors of the organic ion transport a...
Next Document: Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brai...